Interestingly, the comparison of castration-resistant and castration-sensitive matched tumor pairs derived from the same site of origin shows that mutations in the Wnt pathway are more frequent in castration-resistant tumors and, therefore, could contribute to the development of AR resistance in prostate cancer [57]. The gene discussed is AR; the disease is prostate cancer.